Tirzepatide with tesamorelin: no trial has combined them, what each label says on fat and glucose, the one case report, versus questions, and units per draw.
The tirzepatide–tesamorelin pairing is one of the faster-rising stack searches, and "tesamorelin vs tirzepatide" is searched almost as often as the combination. Both questions rest on a picture of two drugs with complementary jobs: one that takes weight off everywhere and one that targets the fat inside the abdomen. The labels support half of that picture each. No study has tested the pair. This page reports what each label and trial says (read 2026-10-07), the one published case report, and the arithmetic for each drug's own vial. It describes; it does not advise.
The single-compound records are on the tirzepatide and tesamorelin dosage pages; the GLP-1 pairing that has been trialled is on the cagrilintide and GLP-1 stack.
The registry, counted
ClinicalTrials.gov returned no study naming both tirzepatide and tesamorelin as interventions on 2026-10-07, and PubMed returned no record for the two names together. Widening the search to tesamorelin with any GLP-1 drug returned six PubMed records: reviews, and one case series, described below. A "tirzepatide tesamorelin protocol" found online is therefore built from two separate labels, not from a study of the pair.
What each label says
|
Tesamorelin (EGRIFTA WR / SV) |
Tirzepatide (ZEPBOUND / MOUNJARO) |
| Class |
GHRH analogue |
GIP + GLP-1 receptor agonist |
|---|
| Labelled dose |
1.28 mg (WR) or 1.4 mg (SV) once daily |
2.5 mg weekly, rising in 2.5 mg steps to 5, 10 or 15 mg |
|---|
| Indication |
Excess abdominal fat in HIV lipodystrophy |
Weight reduction (Zepbound); type 2 diabetes (Mounjaro) |
|---|
| Body weight |
"Weight neutral" (label) |
−15.0% to −20.9% at 72 weeks (SURMOUNT-1) |
|---|
| Visceral fat |
−15.2% vs +5.0% at 26 weeks (2 mg, pivotal trial) |
Reduced vs insulin degludec on MRI (SURPASS-3 substudy) |
|---|
| Glucose |
Warning: glucose intolerance |
Lowers glucose (Mounjaro indication) |
|---|
| IGF-1 |
Raises it; monitoring required |
Not a GH-axis drug |
|---|
| Form |
Powder reconstituted daily or weekly |
Ready-made solution in pens and vials |
|---|
The idea behind the stack, and its limits
The case for pairing them is a reading of those two columns: tirzepatide lowers body weight broadly, tesamorelin lowers visceral fat without lowering weight, so the two might add. The labels show each effect in its own population. Tesamorelin's evidence is in adults with HIV and abdominal fat accumulation; tirzepatide's weight evidence is in adults with obesity or overweight. No source measures what the second drug adds to the first.
Two label facts point in different directions. Tesamorelin's warning on glucose intolerance (5% against 1% reaching an HbA1c of 6.5% by week 26 in the EGRIFTA WR label) sits beside a drug that lowers glucose. And tesamorelin raises IGF-1, by about 107 ng/mL over 26 weeks in its label's trials, while weight loss itself changes body composition in ways the combination has never been measured against. Neither interaction has been studied.
The one published case report
The closest published record is a 2026 case series of two adults with well-controlled HIV and central fat (Beach et al., Clinical Infectious Diseases 2026, PMID 42139091). The first received tesamorelin alone. The second, a woman with obesity, had been on a GLP-1 agonist, not named in the abstract, with intermittent access and fluctuating weight; tesamorelin was then added, which the authors describe as "a more targeted approach". The report gives no doses in its abstract, has no comparison group, and two of its four authors are employees of Theratechnologies, the company that markets tesamorelin. It is a description of two patients, not evidence for the pair.
Reconstitution and the units per draw
The two drugs have different rhythms on their labels, tesamorelin daily and tirzepatide weekly, and come from separate vials:
| Amount |
4 mg/mL |
5 mg/mL |
10 mg/mL |
| Tesamorelin 1.28 mg |
32 units |
25.6 units |
12.8 units |
| Tesamorelin 1.4 mg |
35 units |
28 units |
14 units |
| Tirzepatide 2.5 mg |
62.5 units |
50 units |
25 units |
| Tirzepatide 5 mg |
125 units |
100 units |
50 units |
At the EGRIFTA SV concentration of 4 mg/mL, 1.4 mg is the label's 0.35 mL, 35 units. A 5 mg research vial of tesamorelin with 1 mL gives 5 mg/mL; a 10 mg tirzepatide vial with 1 mL gives 10 mg/mL. Over a week of label doses that is seven tesamorelin draws, 8.96 to 9.8 mg in total, and one tirzepatide draw. Neither label describes combining the two in one syringe or vial. The arithmetic for any vial and volume is on the tesamorelin calculator and the tirzepatide calculator; tirzepatide at every compounded concentration is on tirzepatide units.
No dose for the combination exists, because no one has studied it. The label doses above are each drug's own, set in its own population, and say nothing about the other drug's presence. Tesamorelin's other pairing searched as a stack, with ipamorelin, is a different question again, set out on the tesamorelin and ipamorelin stack. The compounds are covered in Medibact's Tesamorelin guide and Tirzepatide guide. Nothing on this page is an instruction; whether to use either drug, or both, belongs with a prescriber.
Sources and dates
Opened 2026-10-07: ClinicalTrials.gov intervention search for both names; PubMed searches "tesamorelin AND tirzepatide" and "tesamorelin AND (semaglutide OR GLP-1 OR liraglutide)"; the EGRIFTA WR label (DailyMed set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, effective 2026-07-29), sections 1, 2, 5.2, 5.4 and 14; PubMed abstracts 42139091 and 35468325. Carried from this site's pages, each with its read date: the EGRIFTA SV label and the Falutz 2007 trial (tesamorelin page, 2026-09-18), the Zepbound and Mounjaro labels and SURMOUNT-1 (tirzepatide page, 2026-09-18; label versions published 2026-09-02). Units arithmetic by this site. Corrections go to the contact page.
